| Project/Area Number |
21390010
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | Nagasaki University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TO Hideto 富山大学, 大学院・医学薬学研究部(薬学), 教授 (90346809)
KAWAKAMI Shigeru 京都大学, 薬学研究科, 講師 (20322307)
KUROSAKI Tomoaki 長崎大学, 病院・薬剤部, COE研究員 (00582016)
KITAHARA Takashi 長崎大学, 長崎大学病院, 准教授 (30380934)
KODAMA Yukinobu 長崎大学, 大学院・医歯薬学総合研究科, 助教 (50448510)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥18,720,000 (Direct Cost: ¥14,400,000、Indirect Cost: ¥4,320,000)
Fiscal Year 2011: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2010: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2009: ¥10,790,000 (Direct Cost: ¥8,300,000、Indirect Cost: ¥2,490,000)
|
|---|
| Keywords | ドラッグデリバリー / 遺伝子 / 癌 / ナノ材料 / 遺伝子デリバリー / 葉酸 / グリチルリチン / Drug delivery system / 生体適合型ベクター / 生体分解型ベクター / 自己組織化 / 遺伝子導入技術 / 静電的相互作用 / 低分子リガンド / カチオン性遺伝子ベクター / ナノ微粒子 / 遺伝子導入 / アニオン性高分子 / γ-polyglutamic acid / chondroitin sulfate |
|---|
| Research Abstract |
In this study, we developed the self-assembly nano-devices based on electrostatic interaction. We could prepare the stable nano-devices by changing the blend ratio of gene, cationic compounds and anionic compounds and the preparation procedures. The nano-devices containingγ-polyglutamic acid, N-lauroylsarcosine, or glycyrrhizin achieved high intracellular uptake without showing cytotoxicity and blood toxicity. After intravenous administration of these nano-devices in mice, selective high gene expression was observed in the spleen, lung, or liver by the difference of each component. Furthermore, we could mass-produce and freeze-dry nano-devices. In conclusion, we successfully developed the secure and effective nano-devices and revealed the preparation technic responding to therapeutic purpose.
|
